Organovo (ONVO) Competitors $0.36 -0.01 (-3.28%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ONVO vs. INKT, CMMB, EQ, CLDI, ATHA, LSTA, PULM, INAB, GOVX, and IBIOShould you be buying Organovo stock or one of its competitors? The main competitors of Organovo include MiNK Therapeutics (INKT), Chemomab Therapeutics (CMMB), Equillium (EQ), Calidi Biotherapeutics (CLDI), Athira Pharma (ATHA), Lisata Therapeutics (LSTA), Pulmatrix (PULM), IN8bio (INAB), GeoVax Labs (GOVX), and iBio (IBIO). These companies are all part of the "pharmaceutical products" industry. Organovo vs. MiNK Therapeutics Chemomab Therapeutics Equillium Calidi Biotherapeutics Athira Pharma Lisata Therapeutics Pulmatrix IN8bio GeoVax Labs iBio MiNK Therapeutics (NASDAQ:INKT) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, community ranking, media sentiment, risk, profitability and institutional ownership. Is INKT or ONVO more profitable? MiNK Therapeutics has a net margin of 0.00% compared to Organovo's net margin of -12,176.70%. MiNK Therapeutics' return on equity of 0.00% beat Organovo's return on equity.Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -189.14% Organovo -12,176.70%-249.28%-159.50% Do insiders & institutionals have more ownership in INKT or ONVO? 2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 8.2% of Organovo shares are held by institutional investors. 19.7% of MiNK Therapeutics shares are held by company insiders. Comparatively, 3.7% of Organovo shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, INKT or ONVO? MiNK Therapeutics has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Comparatively, Organovo has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Does the MarketBeat Community favor INKT or ONVO? Organovo received 181 more outperform votes than MiNK Therapeutics when rated by MarketBeat users. However, 75.00% of users gave MiNK Therapeutics an outperform vote while only 47.34% of users gave Organovo an outperform vote. CompanyUnderperformOutperformMiNK TherapeuticsOutperform Votes1575.00% Underperform Votes525.00% OrganovoOutperform Votes19647.34% Underperform Votes21852.66% Which has higher earnings and valuation, INKT or ONVO? Organovo has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$22.46M-$0.39-1.34Organovo$103K53.71-$14.67M-$1.06-0.34 Does the media favor INKT or ONVO? In the previous week, MiNK Therapeutics had 1 more articles in the media than Organovo. MarketBeat recorded 1 mentions for MiNK Therapeutics and 0 mentions for Organovo. MiNK Therapeutics' average media sentiment score of 0.00 equaled Organovo'saverage media sentiment score. Company Overall Sentiment MiNK Therapeutics Neutral Organovo Neutral Do analysts rate INKT or ONVO? MiNK Therapeutics currently has a consensus price target of $6.50, suggesting a potential upside of 1,140.46%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than Organovo.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Organovo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryMiNK Therapeutics beats Organovo on 9 of the 16 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Organovo News Delivered to You Automatically Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONVO vs. The Competition Export to ExcelMetricOrganovoBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.72M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-0.3446.7389.9717.18Price / Sales53.71415.011,116.21116.99Price / CashN/A182.1042.8937.86Price / Book1.003.894.784.78Net Income-$14.67M-$42.21M$120.23M$225.60M7 Day Performance-11.02%-2.15%-1.92%-1.23%1 Month Performance5.88%4.20%11.49%3.36%1 Year Performance-67.57%18.39%30.57%16.60% Organovo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONVOOrganovoN/A$0.36-3.3%N/A-67.0%$5.72M$103,000.00-0.3420Analyst ForecastINKTMiNK Therapeutics2.2354 of 5 stars$0.60-2.6%$6.50+983.3%-47.6%$23.73MN/A-1.4930Gap UpCMMBChemomab Therapeutics3.3163 of 5 stars$1.65+4.4%$7.33+344.4%+230.1%$23.69MN/A-1.5820Positive NewsEQEquillium2.9048 of 5 stars$0.66-6.9%$5.00+662.2%-16.5%$23.24M$45.91M-5.0440Gap DownCLDICalidi Biotherapeutics2.039 of 5 stars$1.76-5.1%$16.67+849.7%N/A$22.95M$50,000.000.0041News CoverageGap DownATHAAthira Pharma2.111 of 5 stars$0.580.0%$13.83+2,265.5%-72.6%$22.61MN/A-0.2140LSTALisata Therapeutics1.9029 of 5 stars$2.64+2.3%$15.00+468.2%-5.4%$22.16MN/A-1.1030PULMPulmatrix0.1934 of 5 stars$6.00+4.3%N/A+209.2%$21.90M$7.30M-2.1820Analyst ForecastNews CoverageINABIN8bio3.6424 of 5 stars$0.30+4.1%$7.75+2,512.9%-82.2%$21.50MN/A-0.3820Gap UpGOVXGeoVax Labs2.9319 of 5 stars$2.27-3.4%$14.20+525.6%-54.8%$21.42M$3.09M0.0017Analyst ForecastNews CoverageIBIOiBio0.988 of 5 stars$2.31flat$4.30+86.1%N/A$21.13M$175,000.000.00100 Related Companies and Tools Related Companies MiNK Therapeutics Competitors Chemomab Therapeutics Competitors Equillium Competitors Calidi Biotherapeutics Competitors Athira Pharma Competitors Lisata Therapeutics Competitors Pulmatrix Competitors IN8bio Competitors GeoVax Labs Competitors iBio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ONVO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organovo Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organovo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
